Biogen News and Research

RSS
Amorfix fiscal 2011 net loss decreases to $3,330,437

Amorfix fiscal 2011 net loss decreases to $3,330,437

PDL revises revenue guidance for second quarter 2011 to $122M

PDL revises revenue guidance for second quarter 2011 to $122M

EC approves Biogen Idec's AVONEX PEN to treat multiple sclerosis

EC approves Biogen Idec's AVONEX PEN to treat multiple sclerosis

Positive data from Biogen Idec's AVONEX clinical trial on multiple sclerosis presented at CMSC 2011

Positive data from Biogen Idec's AVONEX clinical trial on multiple sclerosis presented at CMSC 2011

Protox reports net and comprehensive loss of $2.2 million for first quarter 2011

Protox reports net and comprehensive loss of $2.2 million for first quarter 2011

Biogen Idec joins global multiple sclerosis community to celebrate third annual World MS Day

Biogen Idec joins global multiple sclerosis community to celebrate third annual World MS Day

Biogen Idec launches educational forum, 'Women in MS'

Biogen Idec launches educational forum, 'Women in MS'

EMA CHMP recommends conditional marketing authorization of FAMPYRA

EMA CHMP recommends conditional marketing authorization of FAMPYRA

Australian TGA approves Biogen Idec's FAMPYRA to improve walking ability in patients with MS

Australian TGA approves Biogen Idec's FAMPYRA to improve walking ability in patients with MS

EMA agrees to Swedish Orphan Biovitrum, Biogen Idec's pediatric rFIXFc trial in hemophilia

EMA agrees to Swedish Orphan Biovitrum, Biogen Idec's pediatric rFIXFc trial in hemophilia

Acorda reports $0.7 million GAAP net loss for first quarter 2011

Acorda reports $0.7 million GAAP net loss for first quarter 2011

Decision Resources: 63% of neurologists select Tysabri as effective MS treatment

Decision Resources: 63% of neurologists select Tysabri as effective MS treatment

Biogen Idec first quarter revenues increase 9% to $1.2 billion

Biogen Idec first quarter revenues increase 9% to $1.2 billion

FDA approves Rituxan-corticosteroid combination for Wegener's Granulomatosis and Microscopic Polyangiitis

FDA approves Rituxan-corticosteroid combination for Wegener's Granulomatosis and Microscopic Polyangiitis

EMA CHMP grants positive opinion for Biogen Idec's AVONEX PEN

EMA CHMP grants positive opinion for Biogen Idec's AVONEX PEN

CHMP adopts EU positive opinion for TYSABRI labeling with anti-JCV antibody status

CHMP adopts EU positive opinion for TYSABRI labeling with anti-JCV antibody status

Positive top-line results from Biogen BG-12 Phase 3 trial in RRMS

Positive top-line results from Biogen BG-12 Phase 3 trial in RRMS

Anergis SA closes funding round for allergy vaccines

Anergis SA closes funding round for allergy vaccines

Study to identify drug targets for rheumatoid arthritis patients not responding to anti-TNF therapies

Study to identify drug targets for rheumatoid arthritis patients not responding to anti-TNF therapies

EHSI to sign definitive agreement with OceanBASIS

EHSI to sign definitive agreement with OceanBASIS